Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11739071
APP PUB NO 20210130321A1
SERIAL NO

17096349

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • VALO HEALTH, INC.

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Buckmelter, Alexandre Joseph Acton, US 33 576
Campbell, Ann-Marie Monroe, US 71 1371
Follows, Bruce Littleton, US 32 562
Ioannidis, Stephanos Natick, US 56 726
Lancia,, Jr David R Boston, US 128 2026
Talbot, Adam Charles Watertown, US 28 552
Wang, Minghua Acton, US 48 648

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Feb 28, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 28, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 28, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00